Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
Bioxytran (OTCQB: BIXT) has released a preprint article exploring the potential enhancement of cancer immunotherapy through galectin-3 modulation. The research focuses on improving Immune Checkpoint Inhibitors (ICIs) effectiveness in cancer treatment. Key findings show that high galectin-3 levels correlate with treatment failure, with 90% of Non-Small Cell Lung Cancer patients with elevated levels failing to respond after three treatments.
The study reveals that galectin-3 protein interferes with ICI therapy by occupying the antibody's PD-1 receptor binding site, preventing effective treatment. However, in vitro tests indicate that galectin-3 antagonists could potentially reverse this effect. The company also published a presentation on cancer metastasis, highlighting the 'Galectin Effect' as cancer's primary defense mechanism against immune response.
Bioxytran (OTCQB: BIXT) ha pubblicato un articolo preprint che esplora il potenziale miglioramento dell'immunoterapia del cancro attraverso la modulazione della galectina-3. La ricerca si concentra sul miglioramento dell'efficacia degli Inibitori dei Punti di Controllo Immunitario (ICI) nel trattamento del cancro. I risultati principali mostrano che livelli elevati di galectina-3 sono correlati al fallimento del trattamento, con il 90% dei pazienti con carcinoma polmonare non a piccole cellule con livelli elevati che non rispondono dopo tre trattamenti.
Lo studio rivela che la proteina galectina-3 interferisce con la terapia ICI occupando il sito di legame del recettore PD-1 dell'anticorpo, impedendo un trattamento efficace. Tuttavia, i test in vitro indicano che gli antagonisti della galectina-3 potrebbero potenzialmente invertire questo effetto. L'azienda ha anche pubblicato una presentazione sulla metastasi del cancro, evidenziando l' 'Effetto Galectina' come il principale meccanismo di difesa del cancro contro la risposta immunitaria.
Bioxytran (OTCQB: BIXT) ha publicado un artículo preprint que explora la posible mejora de la inmunoterapia contra el cáncer a través de la modulación de la galectina-3. La investigación se centra en mejorar la efectividad de los Inhibidores de Puntos de Control Inmunitario (ICI) en el tratamiento del cáncer. Los hallazgos clave muestran que los niveles altos de galectina-3 están correlacionados con el fracaso del tratamiento, con el 90% de los pacientes con cáncer de pulmón de células no pequeñas con niveles elevados que no responden después de tres tratamientos.
El estudio revela que la proteína galectina-3 interfiere con la terapia ICI al ocupar el sitio de unión del receptor PD-1 del anticuerpo, lo que impide un tratamiento efectivo. Sin embargo, las pruebas in vitro indican que los antagonistas de la galectina-3 podrían potencialmente revertir este efecto. La empresa también publicó una presentación sobre la metástasis del cáncer, destacando el 'Efecto Galectina' como el principal mecanismo de defensa del cáncer contra la respuesta inmunitaria.
Bioxytran (OTCQB: BIXT)은 갈렉틴-3 조절을 통해 암 면역 요법의 향상 가능성을 탐구하는 프리프린트 기사를 발표했습니다. 연구는 암 치료에서 면역 체크포인트 억제제(ICI)의 효과를 개선하는 데 초점을 맞추고 있습니다. 주요 발견은 높은 갈렉틴-3 수치가 치료 실패와 연관이 있다는 것이며, 높이 올라간 수준의 비소세포 폐암 환자 90%가 세 번의 치료 후 반응하지 않았습니다.
이 연구는 갈렉틴-3 단백질이 항체의 PD-1 수용체 결합 부위를 차지하여 ICI 요법에 간섭함으로써 효과적인 치료를 방해한다는 것을 밝혔습니다. 그러나 시험관 내 실험에서는 갈렉틴-3 길항제가 이 효과를 잠재적으로 되돌릴 수 있음을 나타냅니다. 또한, 이 회사는 암 전이에 대한 발표를 게재하며 '갈렉틴 효과'를 면역 반응에 대한 암의 주요 방어 메커니즘으로 강조했습니다.
Bioxytran (OTCQB: BIXT) a publié un article préimprimé explorant le potentiel d'amélioration de l'immunothérapie du cancer grâce à la modulation de la galectine-3. La recherche se concentre sur l'amélioration de l'efficacité des Inhibiteurs des Points de Contrôle Immunitaire (ICI) dans le traitement du cancer. Les principales conclusions montrent que des niveaux élevés de galectine-3 sont corrélés à un échec du traitement, avec 90 % des patients atteints de cancer du poumon non à petites cellules avec des niveaux élevés ne répondant pas après trois traitements.
L'étude révèle que la protéine galectine-3 interfère avec la thérapie ICI en occupant le site de liaison du récepteur PD-1 de l'anticorps, empêchant un traitement efficace. Cependant, les tests in vitro indiquent que les antagonistes de la galectine-3 pourraient potentiellement inverser cet effet. L'entreprise a également publié une présentation sur la métastase du cancer, mettant en avant l' 'Effet Galectine' comme principal mécanisme de défense du cancer contre la réponse immunitaire.
Bioxytran (OTCQB: BIXT) hat einen Preprint-Artikel veröffentlicht, der das Potenzial zur Verbesserung der Krebsimmuntherapie durch die Modulation von Galektin-3 untersucht. Die Forschung konzentriert sich auf die Verbesserung der Wirksamkeit von Immun-Checkpoint-Inhibitoren (ICI) bei der Krebsbehandlung. Wichtige Ergebnisse zeigen, dass hohe Galektin-3-Spiegel mit einem Behandlungsversagen korrelieren, wobei 90 % der Patienten mit nicht-kleinzelligem Lungenkarzinom bei erhöhten Spiegeln nach drei Behandlungen nicht ansprechen.
Die Studie zeigt, dass das Galektin-3-Protein die ICI-Therapie stört, indem es den Bindungsbereich des PD-1-Rezeptors des Antikörpers besetzt und damit eine effektive Behandlung verhindert. Allerdings deuten In-vitro-Tests darauf hin, dass Galektin-3-Antagonisten diese Wirkung möglicherweise umkehren könnten. Das Unternehmen hat auch eine Präsentation zur Krebsmetastasierung veröffentlicht und dabei den 'Galektin-Effekt' als primären Abwehrmechanismus des Krebses gegen die Immunantwort hervorgehoben.
- Discovery of galectin-3's role in immunotherapy resistance provides new treatment pathway
- In vitro tests show potential for galectin-3 antagonists to improve cancer treatment effectiveness
- Research supported by over 4,000 peer-reviewed articles on galectins in cancer
- 90% treatment failure rate in NSCLC patients with high galectin-3 levels
- Current immunotherapy treatments shown to be ineffective against high galectin-3 expressing tumors
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients” (the “Article”) authored by Dr. Adesuyi Ajayi, Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance.
Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients
http://dx.doi.org/10.13140/RG.2.2.31077.31202
The Article discusses the potential of immune checkpoint inhibitors (ICIs) in cancer treatment and explores how galectin-3 modulation might enhance ICI effectiveness. It highlights the importance of overcoming resistance to ICIs and improving patient outcomes by targeting galectin-3, which could increase the objective response rate (ORR) and remission-free survival in oncology patients. Galectin-3 is also a powerful predictive biomarker of ICI failure in Non-Small Cell Lung Cancer (NSCLC) where
ICI resistance due to galectin-3 in the tumor microenvironment is also due to the galectin-3 glycoprotein occupying the antibody’s PD-1 receptor binding site. This was confirmed by Surface Plasmon Resonance (a technique used to study the interactions between molecules by detecting changes in the refractive index near a sensor surface) - and cyrogenic electron microscopy. The galectin-3 protein binds in such a way that it prevents ICI’s from binding to PD-1. This leaves the receptor open to PD-L1 binding which switches off the T-Cells. In vitro tests show that galectin-3 antagonists could reverse this effect.
The Company also published its cancer metastasis presentation titled “Galectin Antagonists in Cancer.” The presentation goes over the various ways that cancer tricks the immune system and the current modalities being used to fight cancer. The “Galectin Effect” was highlighted as cancers primary defense mechanism to downregulate and cloak the cancer from immune response. Shortcomings in current treatments are addressed as well as innovative approaches to address the deficiencies. The heart of the presentation shows that galectins play a key role in the tumor microenvironment, promoting tumor growth, metastasis, and immune suppression. Galectin antagonists may hold the key to overcoming these effects and improve efficacy of other cancer treatments.
Galectin Antagonists in Cancer
https://tinyurl.com/bdcth9j2
"The magnitude of this breakthrough in cancer research cannot be overstated," said Dr. David Platt, CEO of Bioxytran Inc. "Our findings herald a significant shift in cancer treatment paradigms. We've developed a robust theory of cancer and metastasis, identifying Galectin-3 as a pivotal driver of disease progression. This finding elucidates the variable responses in immunotherapy and the development of resistance in other cancer treatments. With over 4,000 peer-reviewed articles examining the role of galectins in cancer, one consensus is clear: they must be inhibited. Our team has synthesized this extensive body of research into the core insights presented in our preprint and cancer presentation. The data unequivocally supports the finding that combining galectin-3 antagonists can significantly enhance treatment response rates."
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran’s molecules achieve virus neutralization. The extent of the carbohydrate structure’s ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What is the significance of Bioxytran's (BIXT) galectin-3 discovery in cancer treatment?
How does galectin-3 affect cancer treatment success rates according to BIXT's research?
What is the 'Galectin Effect' mentioned in BIXT's cancer research?
How can galectin-3 antagonists improve cancer treatment according to BIXT's findings?
What evidence supports BIXT's research on galectin-3 in cancer treatment?
